Zynerba Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Zynerba Pharmaceuticals has a total shareholder equity of $29.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $40.5M and $11.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$35.97m |
| Equity | US$29.02m |
| Total liabilities | US$11.46m |
| Total assets | US$40.48m |
Recent financial health updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29Financial Position Analysis
Short Term Liabilities: ZYNE's short term assets ($39.3M) exceed its short term liabilities ($11.5M).
Long Term Liabilities: ZYNE has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ZYNE is debt free.
Reducing Debt: ZYNE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ZYNE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.5% each year